The first month is a titration phase, not a weight loss phase
For the vast majority of people, no
GIPR agonism contributes to glucose-dependent insulin release and may modulate adipose tissue metabolism
They reduce appetite and food cravings, slow the rate food leaves the stomach, and help you feel fuller for longer after meals, creating the calorie deficit needed for sustained weight loss
For patients who cannot maintain onceweekly dosing (perhaps due to financial constraints), decreasing frequency is likely preferred to simply discontinuing their GLP1 therapy, since complete discontinuation typically results in regaining two thirds of the lost weight within 1 year
The first group received a placebo every day for 8 weeks, the second group received 1500 mg L-carnitine daily in the form of 2200 milligrams of L-carnitine L-tartrate